0KBU Stock Chart & Stats
$11.57
$0.63(5.76%)
At close: 4:00 PM EDT
$11.57
$0.63(5.76%)
Day’s Range― - ―
52-Week Range$3.97 - $19.62
Previous CloseN/A
Volume155.00
Average Volume (3M)7.43K
Market Cap
$1.32B
Enterprise Value$1.02K
Total Cash (Recent Filing)$131.95M
Total Debt (Recent Filing)$83.77M
Price to Earnings (P/E)10.1
Beta0.03
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.91
Shares Outstanding72,388,310
10 Day Avg. Volume2,495
30 Day Avg. Volume7,434
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$33.00Price Target Upside185.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$68.00M
Bulls Say, Bears Say
Bulls Say
Yartemlia Commercial AdoptionRapid growth in Yartemlia sales and expanding account coverage indicate meaningful physician adoption. Continued penetration across transplant centers could establish a recurring commercial revenue base and improve operating leverage as launch infrastructure scales.
Convertible Debt ReductionRetiring convertible notes reduces future interest expense, refinancing exposure and potential equity dilution. The resulting improvement in capital structure gives Omeros greater financial flexibility while its commercial product and pipeline develop.
Diversified Pipeline And Strategic PartnershipProgress across complement, PDE7 and oncology programs reduces dependence on one asset and preserves multiple growth avenues. The Novo Nordisk relationship also offers external validation, development support and potential milestone funding.
Bears Say
Negative Equity And Constrained Balance SheetNegative equity signals limited balance-sheet resilience and can restrict access to capital on favorable terms. Although debt has fallen materially, the capital structure remains fragile and increases refinancing and execution risk.
Persistent Cash Burn And Weak Earnings QualityOngoing cash outflows and negative operating profit undermine the durability of reported net income. Unless commercial growth converts into sustained operating cash generation, Omeros may remain dependent on financing or asset-related receipts.
European Regulatory Setback And Limited Revenue VisibilityThe European setback narrows near-term geographic expansion and creates additional approval uncertainty. Management’s refusal to guide revenue also limits visibility into launch durability, making planning and forecasting more dependent on emerging prescribing data.
Omeros News
0KBU FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest share price was $3.97 and its highest was $19.61 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $1.32B.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Aug 12, 2026. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.418.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is 0.02.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 72,388,310 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of $0.15 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went up 26.352%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in GB:0KBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (185.22% Upside)
$33.00 (185.22% Upside)
Blogger Sentiment
Bullish
GB:0KBU Sentiment 87%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $276.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
196.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.01%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
0KBU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a successful commercial launch for Yartemlia with very strong quarter-over-quarter sales growth (190% gross, 188% net), positive operating cash flow, meaningful balance sheet improvements via share and note repurchases, reimbursement wins (J-code and NTAP), and progress across a diversified pipeline and strategic partnership with Novo Nordisk. Offsetting items include a negative CHMP opinion in Europe, accounting volatility from derivative mark-to-market adjustments and repurchase-related losses, expected near-term increases in operating expenses, limited patient-level visibility, and one-time reimbursement items that temper recurring income visibility. On balance, the operational and commercial positives—especially the rapid U.S. uptake, cash generation, and reduced leverage/dilution—outweigh the challenges, which are largely manageable or noncash/one-time in nature.View all GB:0KBU earnings summaries0KBU Stock 12 Month Forecast
Average Price Target
$33.00
▲(185.22% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―